Background: Classical Hodgkin's lymphoma (cHL) is a B-cell lymphoid neoplasm characterized by a distinctive biological behavior with potentially curable disease characteristics. It is an uncommon hematological malignancy which primarily affects younger individuals. The rationale of this study was to determine its clinico-hematological profile along with stage strati cation in Pakistani patients.
Materials And Methods: In this descriptive study, adult patients with Hodgkin's lymphoma were enrolled from January 2010 to December 2014.
Results: Sixty two histopathologically con rmed cases of cHL were identified. There were 42 males and 20 females, with a male to female ratio of 2:1. The mean age was 29.7±13.8 years with the median age of 30. B symptoms were present in 72.5% of patients. Histopathologically, the mixed cellularity type constituted 62.9% of cases, followed by nodular sclerosis in 25.8%, lymphocyte predominant in 9.6% and lymphocyte depleted in 1.6%. Stages I and II were present in 43.5% of patients at disease presentation, with 56.4% in stages III and IV.
Conclusions: Our analysis shows that clinico-pathological features of Hodgkin's lymphoma in Pakistan are comparable to published data. Mixed cellularity is the commonest histological variant and advanced stage at presentation are common findings in our patients.
Download full-text PDF |
Source |
---|
Cancer Med
January 2025
Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
Background: Distinctive heterogeneity characterizes diffuse large B-cell lymphoma (DLBCL), one of the most frequent types of non-Hodgkin's lymphoma. Mitochondria have been demonstrated to be closely involved in tumorigenesis and progression, particularly in DLBCL.
Objective: The purposes of this study were to identify the prognostic mitochondria-related genes (MRGs) in DLBCL, and to develop a risk model based on MRGs and machine learning algorithms.
Cureus
December 2024
Department of Ophthalmology, Hospital Sultanah Nur Zahirah, Kuala Terengganu, MYS.
This is an unusual case of primary central nervous system lymphoma (PCNSL) with isolated third cranial nerve palsy as the initial manifestation. Neurolymphomatosis (NL) is a rare manifestation of PCNSL. While NL is a rare manifestation of PCNSL, primary vitreoretinal lymphoma (PVRL) can be the presenting feature or a later-involved manifestation.
View Article and Find Full Text PDFIntroduction Despite the favorable prognosis of Hodgkin's disease (HD), some patients experience disease recurrence. Therefore, determining recurrence prognostic factors is very crucial to identify patients at risk of early relapse, maintain remission, and improve outcomes. Materials and methods This retrospective cohort study enrolled HD patients at the National Research Institute of Tuberculosis and Lung Disease (NRITLD), Masih Daneshvari Hospital, between January 1, 2002, and June 30, 2018.
View Article and Find Full Text PDFJ Obstet Gynaecol
December 2025
Department of Pediatrics, Obstetrics and Gynecology, Universitat de Valencia, Valencia, Spain.
Background: Research on fertility preservation among women diagnosed with lymphoma is very limited. We aimed to assess the receipt of fertility preservation information and use of fertility preservation among women diagnosed with lymphoma.
Methods: This was a retrospective, single-centre study.
Pilot Feasibility Stud
January 2025
Department of Internal Medicine - Cardiology, Virginia Commonwealth University, West Hospital 8th Floor, North Wing, Richmond, VA, 23298, USA.
Background: To determine the feasibility, acceptability, and preliminary efficacy of a 6-month tailored non-linear progressive physical activity intervention (PAI) for lymphoma patients undergoing chemotherapy.
Methods: Patients newly diagnosed with lymphoma (non-Hodgkin (NHL) or Hodgkin (HL)) were randomized into the PAI or healthy living intervention (HLI) control (2:1). Feasibility was assessed by examining accrual, adherence, and retention rates.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!